CME Empowerment Series 2022
Our Continuing Medical Education (CME) Empowerment Series aims to provide effective platforms for medical professionals to acquire, share, and exchange knowledge from clinical experience.
The year's CME presentations bring the latest updates on cancer management and offer insights on our multi-disciplinary approach to the treatment of major and rare cancers to doctors and specialists. New services such as Chimeric Antigen Receptor (CAR) T-cell Therapy and Proton Therapy and their impact on delivering better clinical outcomes for patients would also be covered.
View our key CME sessions here.
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Radiation Oncology
Parkway Cancer Centre
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Unlike many other solid tumours such as breast and colon cancers, adjuvant treatment has not been used widely for resected renal cell carcinoma at high risk of relapse. Sunitinib, an oral multikinase inhibitor is approved by FDA but not HSA, based on single study that showed improvement in disease-free survival, but no impact on overall survival. Various other trials of multikinase inhibitors, failed to show any benefit in adjuvant setting.
There is extensive interest in the role of adjuvant immunotherapy for resected renal cell carcinoma, given immunotherapy is the pillar of front-line treatment of metastatic renal cell carcinoma. In 2021, adjuvant Pembrolizumab resulted in significant improvement in disease-free survival for intermediate or high-risk renal cell carcinoma post resection. Based on this positive results, FDA and EMA has approved the use in this setting. Other large trials have reported recently with mixed results. Small renal tumours may be effectively treated with local therapy. Results from local treatment experience will be shared.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Deputy Medical Director and Senior Consultant
Medical Oncology
Parkway Cancer Centre
Urologist
Mount Elizabeth Hospital
Senior Consultant
Urologist
Gleneagles Hospital
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
Speakers
Deputy Medical Director and Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Medical Oncology
Parkway Cancer Centre
.png?sfvrsn=946245fc_2)
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Cardiothoracic Surgery
Gleneagles Hospital
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Proton Therapy will soon be available in Singapore.
Proton particles have special characteristics that reduce the exposure of normal tissues to radiation.
We will discuss how it is applied to the treatment of prostate cancer and consider the potential benefits.
We will also discuss on refining the treatment for oligometastatic prostate cancer.
Speakers
Senior Consultant
Radiation Oncology
Parkway Cancer Centre
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Lung cancer is the third most common cancer in Singaporean men and women. There have been many advances in treatment with targeted therapy and immunotherapy, and the survival of advanced stage lung cancer patients have significantly improved. Join our multi-disciplinary team discussion on how the latest surgical, radiation, and systemic treatment advancements may further improve the survival of lung cancer patients.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Radiation Oncology
Parkway Cancer Centre
Senior Consultant
Thoracic Surgeon
Gleneagles Hospital
Parkway Cancer Centre (PCC) Tumour Board is a multidisciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
HER2 overexpressed breast cancer tends to affect younger patients compared to HER2 negative breast cancer. Fortunately, overall survival and cure have increased in the last 20 years due to the expansion of therapeutic options. For patients with Low volume disease the key is to find treatments that are compatible with long term preservation of function and quality of life.
We will provide two cases to illustrate the different options of treatment with radiation chemotherapy and localised treatment with discussions from a panel of colleagues.
- Case 1- management of soft tissue only failure
- Case 2- management of brain only failure
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Professor Sherene Loi
Senior Consultant
Medical Oncology
Peter MacCallum Cancer Centre
Senior Consultant
Radiation Oncology
Parkway Cancer Centre
General Surgeon and Oncoplastic Breast Surgeon
Gleneagles Hospital
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Rare cancers are variably defined as having an incidence rate less than 5-15 per 100,000 persons per year. Collectively, up to a quarter of cancers may fall into the umbrella of rare cancers.
Depending on genetic profiles, ethnicity, geography, and other modifiable risk factors, the types of rare cancers encountered vary significantly from place to place. Due to small patient numbers, robust clinical data guiding care is oftentimes absent.
However, the advent of routine tumour molecular testing and its wide-spread adoption in clinical use has opened up an entire treatment paradigm for our patients. In this lecture, we aim to shine the spotlight on rare cancers, and share the opportunities and challenges that lie ahead in these diseases.
- Highlight the various types of rare cancers
- Highlight the challenges associated with management of patients with these rare cancers.
- Discuss the challenges and opportunities in studying these rare cancers
Speaker
.png?sfvrsn=9eba5a07_2)
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
In this coming Tumour Board, we will cover a few cases of challenging common blood cancer. We will present/ discuss :
- A case of leukemia with uncommon presentation with challenging management.
- A case of refractory lymphoma successfully treated with CAR T-cells.
- A case with CA colon and hemolytic anaemia.
Speakers
Senior Consultant
Haematology
Parkway Cancer Centre
-copy.webp)
Senior Consultant
Haematology
Parkway Cancer Centre
Senior Consultant
Haematology
Parkway Cancer Centre
Senior Consultant
Gastroenterologist
Gleneagles Hospital
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Prostate cancer is the third most common cancer among Singaporean men. The number of prostate cancer cases in Singapore has doubled in the last two decades. It is estimated that 30% of prostate cancer patients present at stage 4, typically with cancer having spread to bones. The historical standard treatment of metastatic castration-sensitive prostate cancer is androgen deprivation therapy (ADT) alone. Even though the majority of patients respond to ADT, all patients will develop further cancer progression. Recent trials have shown that early treatment intensification strategy by adding chemotherapy and/or novel hormonal agent to ADT significantly improves overall survival.
Speaker
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
In this upcoming tumour board, a series of 5 interesting, challenging, difficult and unusual cases will be discussed:
- Merkel cell carcinoma I
- Merkel cell carcinoma II
- MPNST (malignant peripheral nerve sheath tumour)
- Cardiac sarcoma
- Thyroid cancer
Speaker
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Otolaryngologist/Head & Neck Surgeon
Mount Elizabeth Hospital
Senior Consultant
Cardiovascular and Thoracic Surgeon
Mount Elizabeth Novena Hospital
Senior Consultant
Head & Neck and General Surgeon
Mount Elizabeth Novena Hospital
Senior Consultant
Orthopaedic Surgeon
Mount Elizabeth Novena Hospital
Dr Colin Tan
Consultant
Nuclear Medicine Physician and Radiologist
Parkway Hospitals
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
In this upcoming tumour board, we will cover locally advanced and metastatic gastroenteropancreatic neuroendocrine tumours(GEP-NET):
- Case presentation of an Appendiceal carcinoid case by Dr Quah Hak Mien
- Discussion on pathology of neuroendocrine tumours and discussion on appendiceal carcinoid, indications for hemicolectomy and adjuvant treatment.
- Case presentation of metastatic GEP-NET cases by Dr Foo Kian Fong.
- Discussion on management of advanced GEP NET
- Discussion on emerging use of peptide related radiotherapy (PRRT) in treatment of GEP NET
Speaker
Senior Consultant
Medical Oncology
Parkway Cancer Centre
.png?sfvrsn=629f59ee_2)
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Consultant Colorectal and General Surgeon
Gleneagles Medical Centre
Medical Director & Senior Consultant Surgeon
Mount Elizabeth Hospital
Dr Colin Tan
Consultant
Nuclear Medicine Physician and Radiologist
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.
In this upcoming tumour board, we focus on the topic of high-risk muscle-invasive bladder cancer and metastatic bladder cancer.
- Case presentation of a muscle-invasive bladder cancer case by Dr Poh Beow Kiong
- Discussion on challenges of clinical staging in muscle invasive bladder cancer, indications and benefit of multimodality treatment
- Case presentation of a metastatic bladder cancer by Dr Lee Fang Jann
- Discussion on clinical factors to consider in treatment selection in first line metastatic bladder cancer and role of maintenance immunotherapy
- Discussion on emerging new drugs in metastatic bladder cancer
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Dr Brendan Pang
Consultant Pathologist
ParkwayHealth Laboratory Services
Urologist
Mount Elizabeth Hospital
Dr Lee Fang Jann
Consultant Urologist
URODOC
Over the last 15 years The Cancer Genome Atlas Program, a joint effort between the National Cancer Institute and The National Human Genome Research Institute, have characterized over 20,000 primary cancers and their outcomes. That has translated to changes to guidelines as to how we recommend treatment to our patients with endometrial cancer. Histologically bizarre subtypes that had traditionally been associated with potentially unfavourable characteristics can be subtypes to a molecularly favourable pattern though next generation sequencing and histological correlation. Additional treatments such as radiation or chemotherapy may in turn be non-beneficial to patients with such tumours.
How does that change the way we prognosticate cancer and counsel patients for treatment before surgery and after surgery?
Join Dr See Hui Ti, Dr Chia Yin Nin, Dr Lee Kuo Ann and Ms Tay Ru Jin as they will share scenarios to illustrate a paradigm shift in management of patients with early endometrial cancer.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Gynaecological Oncologist
Obstetrics & Gynaecology
Gynaecology & Oncology Specialists
Senior Consultant
Radiation Oncology
Parkway Cancer Centre
Ms Tay Ru Jin
Lead Genetic Counsellor
Lucence
Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where unusual or challenging oncology cases are presented for discussion.
This tumour board session will focus on lymphoma and acute lymphoblastic lymphoma cases including those that are amenable to anti-CD19 chimeric antigen receptor CAR T-cell therapy.
In addition to our own local cases, Prof Kim of Samsung Medical Center will also provide insight and their experience with the use of the commercial CAR T-cell product.
Speakers
-copy.webp?sfvrsn=273d0377_1)
Senior Consultant
Haematology
Parkway Cancer Centre
Senior Consultant and Clinical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital
Haematologist
Division of Haematology-Oncology Samsung Medical Centre
Sungkyunkwan University School of Medicine
Seoul, Korea
Colorectal cancer is the most commonly diagnosed cancer in Singapore. Fortunately, it is preventable through basic dietary and lifestyle changes. Screening is proven to reduce colorectal cancer-specific mortality, and may also serve as a form of cancer prevention. When colorectal cancer is diagnosed, accurate staging is essential prior to treatment.
While many patients diagnosed with colorectal cancer are treated with curative intent, patients with advanced incurable disease should still be considered for treatment with the aim of meaningfully prolonging life. Treatment modalities include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. The presentation focus will be on indications for specialist referral and guidelines for post-treatment follow-up.
Speakers
Senior Consultant
Medical Oncology
Parkway Cancer Centre
Senior Consultant
Colorectal & General Surgeon
Mount Elizabeth Hospital
DATE
Saturday, 19 February 2022
TIME
2PM – 3PM SGT
PLATFORM
Online Webinar
(Registration closes on 18 February 2022.)